NASDAQ · Health care

Jade Biosciences, Inc. (JBIO)

It posted a net loss of $153.2M. In fiscal 2025 capital spending exceeded operating cash flow by $94.9M. At June 30, 2026 it held $107.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 10, 2026.

Price

$14.42

-2.11% on the day · September 25, 2026

52-week range $8.16 to $28.00

Market cap

$917.1M

What Jade Biosciences, Inc. does

Jade Biosciences, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker JBIO.

Revenue and profit by year

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	n/a	-$113.5M	-$127.4M	-$3.19	-$94.9M
2024	n/a	-$74.6M	-$69.6M	-$2.44	n/a
2023	n/a	-$81.4M	-$75.5M	-$2.87	-$56.9M
2022	n/a	-$53.2M	-$51.5M	-$2.10	-$39.3M
2021	n/a	-$23M	-$23M	-$1.87	-$27.6M
2021	n/a	-$8.9M	-$9.6M	-$40.31	n/a

Next report expected around October 28, 2026.

Estimated from its filing rhythm: about 79 days after its last report of August 10, 2026, its usual gap. Not a date the company has announced. See the report calendar

Latest SEC filings

What Jade Biosciences, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

August 14, 2026
Passive stake changed SCHEDULE 13G/A
August 14, 2026
Passive stake changed SCHEDULE 13G/A
August 10, 2026
Quarterly report 10-Q · period to June 30, 2026
August 10, 2026
Quarterly results 8-K
July 17, 2026
Passive stake (5% or more) SCHEDULE 13G
July 8, 2026
Passive stake changed SCHEDULE 13G/A
July 1, 2026
Material agreement 8-K
June 26, 2026
Executive or director change 8-K
June 11, 2026
Bylaws or fiscal year changed 8-K
June 9, 2026
Activist stake changed SCHEDULE 13D/A

Recent insider filings (Forms 3, 4 and 144): 10, the latest on June 26, 2026. Insider transactions on SEC

Insider trades

What the people running Jade Biosciences, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

Bought (open market)

last 90 days

Sold

last 90 days

All insider filings on SEC.gov · Where insiders are buying across the market

All filings on SEC EDGAR

Questions about JBIO

What does Jade Biosciences, Inc. do?

Jade Biosciences, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker JBIO.

Is Jade Biosciences, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $153.2M.

When did Jade Biosciences, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 10, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake changed from August 14, 2026.

Similar companies

Compare JBIO with

Compare JBIO with any company

Follow JBIO

Get an email when Jade Biosciences, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow JBIO: get an email when it files

Where the numbers come from

Financial figures are the values Jade Biosciences, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.